Over the past several years, a number of biotech companies have made strides in constructing small molecule drugs to target RNA. Now genetic messenger molecules power the coronavirus vaccines developed by BioNTech and Moderna, training the body’s immune system to detect and defend against disease and infection.

INCLUDED IN THIS TRENDLINE

• After years of disappointment, cancer vaccines show new promise
• ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs
• Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle